Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Artru

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Annals of Surgical Oncology|October 27, 2018
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric CohortDaniel Pietrasz, Olivier Turrini, Véronique Vendrely, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical TrialRémy Nicolle, Jean-Baptiste Bachet, Alexandre Harlé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece TrialsJulien Taieb, John Souglakos, Ioannis Boukovinas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2023
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective studyJean-Baptiste Bachet, Pierre Laurent-Puig, Aurelia Meurisse, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
Cancers|July 20, 2019
<i>BRAF</i> Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC StudyLeo Mas, Jean-Baptiste Bachet, Valerie Taly, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 18, 2021
Prognostic factors of colorectal cancer patients with brain metastasesPauline Roussille, Marie Auvray, Damien Vansteene, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Annals of Surgical Oncology|October 27, 2018
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric CohortDaniel Pietrasz, Olivier Turrini, Véronique Vendrely, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical TrialRémy Nicolle, Jean-Baptiste Bachet, Alexandre Harlé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece TrialsJulien Taieb, John Souglakos, Ioannis Boukovinas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2023
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective studyJean-Baptiste Bachet, Pierre Laurent-Puig, Aurelia Meurisse, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
Cancers|July 20, 2019
<i>BRAF</i> Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC StudyLeo Mas, Jean-Baptiste Bachet, Valerie Taly, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 18, 2021
Prognostic factors of colorectal cancer patients with brain metastasesPauline Roussille, Marie Auvray, Damien Vansteene, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
Pageof 9